$1.90
2.99% today
Nasdaq, Apr 01, 05:49 pm CET
ISIN
US65487U1088
Symbol
NKTX
Sector
Industry

Nkarta Inc Stock price

$1.84
+0.09 5.14% 1M
-2.68 59.29% 6M
-0.65 26.10% YTD
-8.98 82.99% 1Y
-9.54 83.83% 3Y
-46.06 96.16% 5Y
-46.06 96.16% 10Y
Nasdaq, Closing price Mon, Mar 31 2025
-0.16 8.00%
ISIN
US65487U1088
Symbol
NKTX
Sector
Industry

Key metrics

Market capitalization $130.56m
Enterprise Value $-56.52m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.54
P/B ratio (TTM) P/B ratio 0.32
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-128.19m
Free Cash Flow (TTM) Free Cash Flow $-104.11m
Cash position $267.35m
EPS (TTM) EPS $-1.66
P/E forward negative
Short interest 17.66%
Show more

Is Nkarta Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,804 stocks worldwide.

Nkarta Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Nkarta Inc forecast:

9x Buy
100%

Analyst Opinions

9 Analysts have issued a Nkarta Inc forecast:

Buy
100%

Financial data from Nkarta Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs 9.15 9.15
22% 22%
-
-9.15 -9.15
22% 22%
-
- Selling and Administrative Expenses 22 22
13% 13%
-
- Research and Development Expense 88 88
4% 4%
-
-119 -119
4% 4%
-
- Depreciation and Amortization 9.15 9.15
22% 22%
-
EBIT (Operating Income) EBIT -128 -128
3% 3%
-
Net Profit -109 -109
7% 7%
-

In millions USD.

Don't miss a Thing! We will send you all news about Nkarta Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Nkarta Inc Stock News

Neutral
GlobeNewsWire
about 5 hours ago
SOUTH SAN FRANCISCO, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the following investor conference:
Positive
Seeking Alpha
one day ago
Nkarta, Inc. has provided significant pipeline updates, showcasing promising advancements in their innovative cell therapy treatments. A financial overview highlights a robust balance sheet, with sufficient cash reserves to support ongoing research and development activities. Strengths include cutting-edge technology and strategic partnerships, while risks involve clinical trial uncertainties a...
Positive
Seeking Alpha
one day ago
Nkarta's NKX019 shows promise in treating autoimmune diseases, despite a 70% stock drop; strategic restructuring extends financial runway to 2029. Q4 and full-year 2024 earnings reveal significant R&D expenses and a net loss, but a strong cash position of $380.5M. Upcoming clinical data from Ntrust-1 and Ntrust-2 trials are key catalysts; positive results could validate NKX019 and attract inves...
More Nkarta Inc News

Company Profile

Nkarta, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of natural killer cell therapies for the treatment of cancer. The company was founded by Dario Campana in 2005 and is headquartered in South San Francisco, CA.

Head office United States
CEO Paul Hastings
Employees 157
Founded 2005
Website www.nkartatx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today